^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta)

    i
    Other names: HLA-DMB, Major Histocompatibility Complex, Class II, DM Beta, RING7, D6S221E, HLA Class II Histocompatibility Antigen, DM Beta Chain, Really Interesting New Gene 7 Protein, MHC Class II Antigen DMB, Class II Histocompatibility Antigen, M Beta Chain, MHC Class II HLA-DMB, DMB
    6ms
    Predictive value of MHC-related genes in cervical cancer: implications for immunotherapy and prognostic nomogram development. (PubMed, Discov Oncol)
    We propose a robust MHCRG-based gene signature, validated through both bioinformatic analyses and in vitro functional experiments. These findings offer translational potential for improving risk stratification and guiding immunotherapy in CC patients.
    Journal • IO biomarker
    |
    HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • CANX (Calnexin)
    10ms
    Decoding the role of lipid metabolism in NSCLC: From macrophage subtype identification to prognostic model development. (PubMed, FASEB J)
    Immune infiltration analysis highlighted the immunological relevance of the identified marker genes, providing insights into their functional roles. This study underscores the critical influence of LAMs in NSCLC progression and highlights a robust prognostic model that offers potential therapeutic targets for improving patient outcomes.
    Journal
    |
    HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta)
    11ms
    Identification of the molecular subtype and prognostic characteristics of lung adenocarcinoma based on CD8+ T cell-related gene signature. (PubMed, Cancer Biomark)
    QRT-PCR detection of Clinical LUAD samples also validated the differentially expression of CDIGPM model related genes.ConclusionsThe study highlights the prognostic importance of CDIGs in LUAD using the CDIGPM model, linking age, stage and CDIGPM score to poor outcomes. The identified genes and pathways provide potential therapeutic targets, deepening our understanding of LUAD's molecular landscape.
    Journal • Gene Signature • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CAV1 (Caveolin 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • S100A16 (S100 Calcium Binding Protein A16) • PTGDS (Prostaglandin D2 Synthase)
    1year
    HLA-DMB correlates with antitumor immunity and an improved prognosis in endometrial carcinoma tumors. (PubMed, Front Oncol)
    In our drug analysis, we identified several chemical agents associated with HLA-DMB, including cisplatin, dexamethasone, and ethinylestradiol. This study elucidates the function and underlying mechanisms of HLA-DMB in UCEC, providing a potential biomarker and target for immunotherapy in this disease.
    Journal • IO biomarker
    |
    CD22 (CD22 Molecule) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta)
    |
    cisplatin • dexamethasone
    1year
    Exploration of metastasis-related signatures in osteosarcoma based on tumor microenvironment by integrated bioinformatic analysis. (PubMed, Heliyon)
    We identified three principal genes as promising signatures for predicting the survival the prognosis of OS patients. Exploration of metastasis-related signatures in TME may be valuable for enhancing treatment strategies for OS.
    Journal
    |
    IRF8 (Interferon Regulatory Factor 8) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta)
    over1year
    Five-gene prognostic model based on autophagy-dependent cell death for predicting prognosis in lung adenocarcinoma. (PubMed, Sci Rep)
    We successfully identified a model based on five ADCD genes to predict disease prognosis and treatment efficacy in LUAD, as well as to assess the tumor immune microenvironment. An efficient and practical ADCDRS nomogram was designed.
    Journal • IO biomarker
    |
    BIRC3 (Baculoviral IAP repeat containing 3) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • TAP1 (Transporter 1)
    almost2years
    Development and Validation of a Machine Learning Prognostic Model of m5C Related immune Genes in Lung Adenocarcinoma. (PubMed, Cancer Control)
    The prognostic signature comprised of HLA-DMB, PPIA, and GPI based on m5C-IRGs was established, which might provide theoretical basis and reference value for the research of LUAD.
    Journal • IO biomarker • Machine learning
    |
    HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • PPIA (Peptidylprolyl Isomerase A)
    almost2years
    Identifying the tumor-associated macrophage of lung adenocarcinoma reveals immune landscape through omics data integration. (PubMed, Heliyon)
    The transcriptional characteristics of 5 genes were determined through GEPIA2 database and RT-qPCR. The increased expression of TUBA1B in advanced LUAD may serve as a prognostic indicator, while low expression of PEBP1 in LUAD may have the potential to become a therapeutic target.
    Journal
    |
    HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • TUBA1B (Tubulin Alpha 1b)
    over2years
    Construction of a novel prognostic model in skin cutaneous melanoma based on chemokines-related gene signature. (PubMed, Sci Rep)
    Based on the finding, we can claim that there is a clear link between chemokines and TME in SKCM. The risk score may perform as a trustworthy prediction model, giving therapeutic benefits for both chemotherapy and immunotherapy, as well as being beneficial for clinical decision making in SKCM patients.
    Journal • Gene Signature • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • IL2RA (Interleukin 2 receptor, alpha) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) • IRF1 (Interferon Regulatory Factor 1) • CCL8 (C-C Motif Chemokine Ligand 8) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • GBP4 (Guanylate Binding Protein 4)
    |
    IRF1 expression
    over2years
    Comprehensive Analyses Revealed Eight Immune Related Signatures Correlated With Aberrant Methylations as Prognosis and Diagnosis Biomarkers for Kidney Renal Papillary Cell Carcinoma. (PubMed, Clin Genitourin Cancer)
    The risk assessment model constructed by those 8 DEGs was well able to predict the prognosis and diagnose of KIRP. However, whether the prognosis and diagnosis model could be applied in clinical practice requires further study.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • VIM (Vimentin) • LIFR (LIF Receptor Subunit Alpha) • NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • MAP3K14 (Mitogen-Activated Protein Kinase Kinase Kinase 14) • SECTM1 (Secreted and transmembrane 1) • LTB4R2 (Leukotriene B4 Receptor 2)
    almost3years
    GENE EXPRESSION PROFILING OF T(14;18)-NEGATIVE CD23+ FOLLICLE CENTER LYMPHOMA DEMONSTRATES ACTIVATION OF THE IL4/JAK/STAT6 PATHWAY AND A ROLE IN ITS PATHOGENESIS (ICML 2023)
    GEP identified two distinct groups within t(14;18)-neg FL, indicating different stages of differentiation of the neoplastic B cells. FLnegmut shows activation of STAT6 pathway through upregulation of CD23 and IL4R and by enrichment in GSEA and correlates with CD23 expression. Constitutive activation of STAT6 and consequent upregulation of CD23 prevent ongoing B cell differentiation in FLnegmut, precluding the cells from exiting the GC and adopting the state of activated B cell.
    IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF17 (TNF Receptor Superfamily Member 17) • JAK1 (Janus Kinase 1) • CD22 (CD22 Molecule) • PAX5 (Paired Box 5) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • S100A8 (S100 Calcium Binding Protein A8) • IRF4 (Interferon regulatory factor 4) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • SOCS1 (Suppressor Of Cytokine Signaling 1) • TYK2 (Tyrosine Kinase 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • CD40 (CD40 Molecule) • FCGR1A (Fc Fragment Of IgG Receptor Ia) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • IL4 (Interleukin 4) • FCER2 (Fc Fragment Of IgE Receptor II) • FCRLA (Fc Receptor Like A) • IL4R (Interleukin 4 Receptor) • SLAMF7 (SLAM Family Member 7) • SOCS3 (Suppressor Of Cytokine Signaling 3) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    |
    SOCS1 mutation
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel